Evidence map›Paper›PMID 27937077›Full record

Trial reportPharmaceutical biology2017

Hypocholesterolemic efficacy of royal jelly in healthy mild hypercholesterolemic adults.

Hui-Fang Chiu, Bo-Kai Chen, Yan-Ying Lu, Yi-Chun Han, You-Cheng Shen, Kamesh Venkatakrishnan, Oksana Golovinskaia, Chin-Kun Wang

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmaceutical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Hui-Fang Chiua Department of Chinese Medicine , Taichung Hospital, Ministry of Health and Well-being , Taichung City , Taiwan, ROC.
Bo-Kai Chenb School of Nutrition, Chung Shan Medical University , Taichung City , Taiwan, ROC.
Yan-Ying Luc Department of Neurology , Chung Shan Medical University , Taichung City , Taiwan, ROC.
Yi-Chun Hanb School of Nutrition, Chung Shan Medical University , Taichung City , Taiwan, ROC.
You-Cheng Shend School of Health Diet and Industry Management, Chung Shan Medical University , Taichung City , Taiwan, ROC.
Kamesh Venkatakrishnanb School of Nutrition, Chung Shan Medical University , Taichung City , Taiwan, ROC.
Oksana Golovinskaiae ITMO University , Saint-Petersburg , Russia.
Chin-Kun Wangb School of Nutrition, Chung Shan Medical University , Taichung City , Taiwan, ROC.
Chung Shan Medical University · TWITMO University · RUTaichung Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextRoyal jelly (RJ) has been reported for its health promoting factors such as antioxidant, anti-inflammatory and lipid lowering activities.

objectiveThe present randomized, placebo-controlled study examines the hypolipidemic beneficial effect of RJ through evaluating anthropometric measurements, lipid profile and various hormone levels in mildly hypercholesterolemic participants. MATERIALS AND

methodsForty subjects with mild hypercholesterolemia (180-200 mg/dL) were randomly selected and divided into two groups as experimental or placebo, who requested to intake nine capsules (350 mg/capsule) of RJ or placebo/day, respectively, for three months with one month of follow-up without any supplementation.

resultsNo significant changes were noted in any of the anthropometric parameters like body weight, waist and body fat. The serum total cholesterol (TC; 207.05-183.15 mg/dL) and low-density lipoprotein cholesterol (LDL-c; 126.44-120.31 mg/dL) levels were reduced significantly (p < 0.05) after administration of RJ. However, triglyceride (TG) and high-density lipoprotein cholesterol (HDL-c) levels were not considerably altered. Moreover, three months of RJ consumption significantly ameliorated (p < 0.05) the concentration of sex hormones like dehydroepiandrosterone sulphate (DHEA-S; 1788.09-1992.31 ng/mL). Also, intake of RJ did not elicit any hepatic or renal damage. DISCUSSION AND

conclusionIntervention with RJ for three months considerably lowered the TC and LDL-c levels through improving the levels of DHEA-S and thus alleviates the risk of cardiovascular disease (CVD).

Indexed as

Anticholesteremic AgentsBiomarkersCardiovascular DiseasesCholesterol, HDLCholesterol, LDLFatty AcidsFemaleGonadal Steroid HormonesHumansHypercholesterolemiaMaleRisk FactorsRoyal JellySingle-Blind MethodTaiwanTime FactorsAnticholesteremic AgentsBiomarkersCholesterol, HDLCholesterol, LDLFatty AcidsGonadal Steroid HormonesRoyal JellyTriglyceridescardiovascular diseasedehydroepiandrosterone sulphatehypercholesterolemiaLipidsroyal jelly

Identifiers

PMID27937077
PMCPMC6130454
OpenAlexW2567602373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.